Recent advances regarding the role of ABC subfamily C member 10(ABCC10) in the efflux of antitumor drugs  

作　　者：Rishil J.Kathawala Yi-Jun Wang Charles R.Ashby Jr Zhe-Sheng Chen 

机构地区：[1]Department of Pharmaceutical Sciences,College of Pharmacy and Health Sciences,St.John’s University

出　　处：《Chinese Journal of Cancer》2014年第5期223-230,共8页

基　　金：supported by funds from the National Institute of Health (No.1R15CA143701);St.John's University Research Seed Grant (No.579-1110-7002) to Z.S.Chen

摘　　要：ABCC10,also known as multidrug-resistant protein 7(MRP7),is the tenth member of the C subfamily of the ATP-binding cassette(ABC) superfamily.ABCC10 mediates multidrug resistance(MDR) in cancer cells by preventing the intracellular accumulation of certain antitumor drugs.The ABCC10 transporter is a 171-kDa protein that is localized on the basolateral cell membrane.ABCC10 is a broad-specificity transporter of xenobiotics,including antitumor drugs,such as taxanes,epothilone B,vinca alkaloids,and cytarabine,as well as modulators of the estrogen pathway,such as tamoxifen.In recent years,ABCC10 inhibitors,including cepharanthine,lapatinib,erlotinib,nilotinib,imatinib,sildenafil,and vardenafil,have been reported to overcome ABCC10-mediated MDR.This review discusses some recent and clinically relevant aspects of the ABCC10 drug efflux transporter from the perspective of current chemotherapy,particularly its inhibition by tyrosine kinase inhibitors and phosphodiesterase type 5 inhibitors.ABCC10, also known as multidrug-resistant protein 7 （MRP7）, is the tenth member of the C subfamily of the ATP-binding cassette （ABC） superfamily. ABCC10 mediates multidrug resistance （MDR） in cancer cells by preventing the intracellular accumulation of certain antitumor drugs. The ABCC10 transporter is a 171-kDa protein that is localized on the basolateral cell membrane. ABCC10 is a broad-specificity transporter of xenobiotics, including antitumor drugs, such as taxanes, epothilone B, vinca alkaloids, and cytarabine, as well as modulators of the estrogen pathway, such as tamoxifen. In recent years, ABCC10 inhibitors, including cepharanthine, lapatinib, erlotinib, nilotinib, imatinib, sildenafil, and vardenafil, have been reported to overcome ABCC10-mediated MDR. This review discusses some recent and clinically relevant aspects of the ABCC10 drug efflux transporter from the perspective of current chemotherapy, particularly its inhibition by tyrosine kinase inhibitors and phosphodiesterase type 5 inhibitors.

关 键 词：抗肿瘤药物 家族 酪氨酸激酶抑制剂 外排 多药耐药 磷酸二酯酶 转运体 埃坡霉素 

分 类 号：R730.5[医药卫生—肿瘤]